Notice2022-20985
Clinical Chemistry and Clinical Toxicology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments; Amendment of Notice
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 28, 2022
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA) is announcing a correction to the notice of meeting of the Clinical Chemistry and Clinical Toxicology Devices Panel of the Medical Devices Advisory Committee. This meeting was announced in the Federal Register of September 2, 2022. The correction is being made to reflect a change to the sponsor's name. There are no other changes.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 187 (Wednesday, September 28, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 187 (Wednesday, September 28, 2022)]
[Notices]
[Pages 58800-58801]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-20985]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2022-N-1914]
Clinical Chemistry and Clinical Toxicology Devices Panel of the
Medical Devices Advisory Committee; Notice of Meeting; Establishment of
a Public Docket; Request for Comments; Amendment of Notice
AGENCY: Food and Drug Administration, HHS.
[[Page 58801]]
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing a
correction to the notice of meeting of the Clinical Chemistry and
Clinical Toxicology Devices Panel of the Medical Devices Advisory
Committee. This meeting was announced in the Federal Register of
September 2, 2022. The correction is being made to reflect a change to
the sponsor's name. There are no other changes.
FOR FURTHER INFORMATION CONTACT: James Swink, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5211, Silver Spring, MD 20993-0002, 301-796-6313,
<a href="/cdn-cgi/l/email-protection#b7fdd6dad2c499e4c0ded9dcf7d1d3d699dfdfc499d0d8c1"><span class="__cf_email__" data-cfemail="f4be95999187daa7839d9a9fb4929095da9c9c87da939b82">[email protected]</span></a>, or FDA Advisory Committee Information Line, 1-
800-741-8138 (301-443-0572 in the Washington, DC area). Please call the
Information Line for up-to-date information on this meeting.
SUPPLEMENTARY INFORMATION: In the Federal Register of September 2, 2022
(87 FR 54221), FDA announced that a meeting of the Clinical Chemistry
and Clinical Toxicology Devices Panel of the Medical Devices Advisory
Committee would be held on October 20, 2022. On page 54222, in the
second column, in the Agenda portion of the document, the second
sentence ``On October 20, 2022, the committee will discuss, make
recommendations, and vote on clinical information related to the De
Novo request for the AvertD Test sponsored by SolvD, Inc.'' is changed
to read as follows: ``On October 20, 2022, the committee will discuss,
make recommendations, and vote on clinical information related to the
De Novo request for the AvertD Test sponsored by SOLVD Health.''
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.
Dated: September 22, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-20985 Filed 9-27-22; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 28, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.